Publication Name	World Journal of Cardiology
Manuscript ID	1834
Country	United States

Received	2013-01-10 09:51
Peer-Review Started	2013-01-16 15:55
To Make the First Decision	2013-02-21 20:57
Return for Revision	2013-02-28 14:38
Revised	2013-03-01 05:20
Second Decision	2013-03-28 17:26
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-03-29 11:58
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-04-22 16:16
Publish the Manuscript Online	2013-04-27 19:02

ISSN	1949-8462 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Review
Article Title	Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets
Manuscript Source	Invited Manuscript
All Author List	Masahito Kawabori, Rachid Kacimi, Joel S Karliner and Midori A Yenari
Funding Agency and Grant Number	Funding Agency Grant Number National Institutes of Health NS40516, to Yenari MA Veteran’s Merit Award to Yenari MA Uehara Foundation (2013 Research Fellowship to Kawabori M National Heart, Lung, and Blood Institute/NHLBI 1P01 HL 68738 (to Karliner JS) National Heart, Lung, and Blood Institute/NHLBI R01 HL 090606 (to Karliner JS) Northern California Institute for Research and Education to Yenari MA and Karliner JS Veterans Affairs Medical Center, San Francisco, California
Corresponding Author	Midori A Yenari, MD, Department of Neurology, San Francisco and San Francisco Veterans Affairs Medical Center, University of California, Neurology (127) VAMC 4150 Clement Street, San Francisco, CA 94121, United States. yenari@alum.mit.edu
Key Words	Sphingolipids; Sphingosine-1-phosphate; Sphingosine kinase; Ceramide kinase
Core Tip	The sphingolipid pathway has received considerable attention recently, because its active metabolites appear to have salutary effects on cytoprotection in experimental cardiac and cerebral ischemia. Both inhibitors and antagonists of the sphingolipid sphingosine-1-phosphate (S1P) pathway appear to limit ischemic injury through a variety of mechanisms. Because of the clinical availability of Fingolimod (FTY720), a S1P analog, for use in multiple sclerosis, preclinical and clinical studies should focus on the development of this and similar pharmaceuticals for a new indication.
Publish Date	2013-04-27 19:02
Citation	Kawabori M, Kacimi R, Karliner JS, Yenari MA. Sphingolipids in cardiovascular and cerebrovascular systems: Pathological implications and potential therapeutic targets. World J Cardiol 2013; 5(4): 75-86
URL	http://www.wjgnet.com/1949-8462/full/v5/i4/75.htm
DOI	http://dx.doi.org/10.4330/wjc.v5.i4.75

Full Article (PDF)	WJC-5-75.pdf
Manuscript File	1834-Review.doc
Answering Reviewers	1834-Answering reviewers.docx
Copyright License Agreement	1834-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	1834-Language cetificate.docx
Peer-review Report	1834-Peer review(s).pdf
Scientific Editor Work List	1834-Scientific editor work list.doc